Company research
Marker Therapeutics, Inc.
CIK 1094038Updated Sep 27, 2026
SecurityMRKR · NASDAQ · equity
Name history
TAPIMMUNE INC. · through Oct 17, 2018TAPIMMUNE INC · through Jun 29, 2017GENEMAX CORP · through Jun 28, 2007EDUVERSE COM · through Jun 17, 2002
MRKR price & chart
Loading TradingView…
NASDAQ:MRKR on TradingView ↗About the company
Marker Therapeutics, Inc. is a Houston, TX-based clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors. The Company was founded at Baylor College of Medicine, and clinical trials that enrolled more than 200 patients across various hematological and solid tumor indications showed that the Company’s autologous and allogeneic MAR-T cell products were well tolerated and demonstrated durable clinical responses. Marker’s goal is to introduce novel T cell therapies to the market and improve patient outcomes. To achieve these objectives, the Company prioritizes the preservation of financial resources and focuses on operational excellence. Marker’s unique T cell platform is strengthened by non-dilutive funding from U.S. state and federal agencies supporting cancer research. The APOLLO study is supported by the National Cancer Institute of the National Institutes of Health under Award Number R44CA291521. The Company’s pancreatic cancer program is supported by the National Cancer Institute of the National Institutes of Health (Award Number R44CA295168), and the Can…
In the news
No coverage from other publishers is available.
Recent filings
10-Q filing
10-Q filing
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders
Items 5.03, 5.07, 9.01
DEFA14A filing
DEF 14A filing
Show 5 more recent filings
ARS filing
Results of Operations and Financial Condition
Items 2.02, 9.01
10-K filing
PRE 14A filing
Shareholder Director Nominations
Items 5.08, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 19,070,997Source | 22,022,860Source | 17,127,391Source | 34,422,184Source |
| Property, Plant and Equipment, NetUSD | — | — | — | 12,323,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 16,068,048Source | 19,192,440Source | 15,111,450Source | 11,782,172Source |
| Assets, CurrentUSD | 19,070,997Source | 22,022,860Source | 17,127,391Source | 16,619,255Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | 5,479,786Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 2,274,183Source | 3,464,454Source | 3,074,848Source | 14,821,147Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 16,672Source | 10,708Source | 8,891Source | 8,406Source |
| Additional Paid in CapitalUSD | 475,960,940Source | 465,564,876Source | 450,329,515Source | 447,641,680Source |
| Retained Earnings (Accumulated Deficit)USD | -459,180,798Source | -447,017,178Source | -436,285,863Source | -428,049,049Source |
| Stockholders' Equity Attributable to ParentUSD | 16,796,814Source | 18,558,406Source | 14,052,543Source | 19,601,037Source |
| Liabilities and EquityUSD | 19,070,997Source | 22,022,860Source | 17,127,391Source | 34,422,184Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 2,274,183Source | 3,464,454Source | 3,074,848Source | 7,781,809Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | 577,198Source |
| Accounts Payable, CurrentUSD | 793,727Source | 1,066,000Source | 961,000Source | 1,612,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | 7,039,338Source |
| Additional Financial Items | ||||
| Deferred Revenue, CurrentUSD | 974,799Source | — | — | 0Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -12,163,620Source | -10,731,315Source | -8,236,814Source | -29,930,694Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | 2,789,106Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 537,540Source | 245,864Source | 858,269Source | 5,344,006Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -12,014,081Source | -10,910,324Source | -16,439,961Source | -26,972,153Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | 18,664,122Source | -4,945,136Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 9,864,488Source | 14,991,314Source | 1,105,117Source | 202,130Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | 11,800,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 17,042,847Source | 19,192,440Source | 15,111,450Source | 11,782,172Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 42,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 537,540Source | 246,000Source | 1,583,000Source | 5,344,000Source |
| DepreciationUSD | — | — | — | 2,800,000Source |
| Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of TaxUSD | — | — | 8,731,487Source | — |
| Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of TaxUSD | — | — | -2,922,406Source | — |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | -25,995Source |
| General and Administrative ExpenseUSD | 4,184,806Source | 4,241,607Source | 7,475,722Source | 12,820,004Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | -10,731,315Source | -14,045,895Source | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | -10,731,315Source | -14,045,895Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | 5,809,081Source | — |
| Income Tax Expense (Benefit)USD | -15,156Source | 49,953Source | 3,675Source | — |
| Investment Income, InterestUSD | 594,206Source | 437,010Source | 539,158Source | 248,063Source |
| Net Income (Loss) Attributable to ParentUSD | -12,163,620Source | -10,731,315Source | -8,236,814Source | -29,930,694Source |
| Operating Costs and ExpensesUSD | 4,568,485Source | 5,853,000Source | 1,620,000Source | — |
| Operating ExpensesUSD | 16,437,095Source | 17,709,452Source | 17,892,511Source | 38,959,327Source |
| Proceeds from Issuance of Common StockUSD | 9,863,883Source | — | 1,014,640Source | 202,130Source |
| Proceeds from Stock Options ExercisedUSD | — | 62,159Source | 90,477Source | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 3,546,669Source | 6,591,080Source | 3,311,133Source | 9,013,544Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -12,890,426Source | -11,118,372Source | -14,581,378Source | -29,945,783Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -12,178,776Source | -10,681,362Source | -14,042,220Source | — |
| Income Tax Expense (Benefit)USD | -15,156Source | 49,953Source | 3,675Source | — |
| Net Income (Loss) Attributable to ParentUSD | -12,163,620Source | -10,731,315Source | -8,236,814Source | -29,930,694Source |
| Earnings Per Share, BasicUSD per share | -0.79Source | -1.19Source | -0.94Source | -3.58Source |
| Earnings Per Share, DilutedUSD per share | -0.79Source | -1.19Source | -0.94Source | -3.58Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 15,310,308Source | 8,980,207Source | 8,809,382Source | 8,351,003Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 15,310,308Source | 8,980,207Source | 8,809,382Source | 8,351,003Source |
| Additional Financial Items | ||||
| Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of TaxUSD | — | — | -2,922,406Source | — |
| General and Administrative ExpenseUSD | 4,184,806Source | 4,241,607Source | 7,475,722Source | 12,820,004Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | -10,731,315Source | -14,045,895Source | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | -10,731,315Source | -14,045,895Source | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | -1.19Source | -1.59Source | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | -1.19Source | -1.59Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | 5,809,081Source | — |
| Investment Income, InterestUSD | 594,206Source | 437,010Source | 539,158Source | 248,063Source |
| Operating Costs and ExpensesUSD | 4,568,485Source | 5,853,000Source | 1,620,000Source | — |
| Operating ExpensesUSD | 16,437,095Source | 17,709,452Source | 17,892,511Source | 38,959,327Source |
| Research and Development ExpenseUSD | 11,799,154Source | 13,467,845Source | 10,416,789Source | 26,139,323Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 3,546,669Source | 6,591,080Source | 3,311,133Source | 9,013,544Source |
Filing attachments
tm268941d1_ex99-1.htm · 8-K · 2026-03-19
EX-99.1 2 tm268941d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature Medicine highlighted promising results of multi-antigen targeted T cells in pancreatic cancer Strengthened manufacturing capabilities through collaboration wit…
Read attachment ↗tm2530894d1_ex99-1.htm · 8-K · 2025-11-14
EX-99.1 2 tm2530894d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma MT-601 demonstrated 66% objective response rate with 50% complete response in relapsed Non-Hodgkin lymphoma (NHL) patients in the ongoing APOLLO study First patient treated in Off-the-Shelf program (RAPID study) investig…
Read attachment ↗tm2530129d1_ex99-1.htm · 8-K · 2025-11-05
EX-99.1 2 tm2530129d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors Houston, TX - November 5, 2025 - Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to the Company’s Board of Director…
Read attachment ↗tm2527906d1_ex99-1.htm · 8-K · 2025-10-06
EX-99.1 2 tm2527906d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatment OTS product was well tolerated - safety data consistent with other MAR-T cell studies Houston, TX - October 6, 2025 - Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-…
Read attachment ↗tm2524197d1_ex99-1.htm · 8-K · 2025-08-26
EX-99.1 2 tm2524197d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphoma showed 66% of Non-Hodgkin Lymphoma (NHL) patients achieving objective response rates, with 50% demonstrating complete response (CR) Favorable safety profile observed in study participants with no dose limiting tox…
Read attachment ↗tm2524197d1_ex99-2.htm · 8-K · 2025-08-26
EX-99.2 3 tm2524197d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 MARKER THERAPEUTICS CORPORATE PRESENTATION August 2025 NASDAQ: MRKR Forward Looking Statements Certain statements contained herein are forward - looking statements within the meaning of Section 21 E of the Securities Exchange Act of 1934, as amended, and Section 27 A of the Securities Act of 1933, as amended, that involve risks and uncertainties. All statements other than statements relating to historical matters including statemen…
Read attachment ↗